These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

867 related articles for article (PubMed ID: 24055090)

  • 1. Epithelial-mesenchymal transition increases during the progression of in situ to invasive basal-like breast cancer.
    Choi Y; Lee HJ; Jang MH; Gwak JM; Lee KS; Kim EJ; Kim HJ; Lee HE; Park SY
    Hum Pathol; 2013 Nov; 44(11):2581-9. PubMed ID: 24055090
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concomitant expression of epithelial-mesenchymal transition biomarkers in breast ductal carcinoma: association with progression.
    Logullo AF; Nonogaki S; Pasini FS; Osório CA; Soares FA; Brentani MM
    Oncol Rep; 2010 Feb; 23(2):313-20. PubMed ID: 20043090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of epithelial-mesenchymal transition-related markers in triple-negative breast cancer: ZEB1 as a potential biomarker for poor clinical outcome.
    Jang MH; Kim HJ; Kim EJ; Chung YR; Park SY
    Hum Pathol; 2015 Sep; 46(9):1267-74. PubMed ID: 26170011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype.
    Ricardo S; Vieira AF; Gerhard R; Leitão D; Pinto R; Cameselle-Teijeiro JF; Milanezi F; Schmitt F; Paredes J
    J Clin Pathol; 2011 Nov; 64(11):937-46. PubMed ID: 21680574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast.
    Steinman S; Wang J; Bourne P; Yang Q; Tang P
    Ann Clin Lab Sci; 2007; 37(2):127-34. PubMed ID: 17522367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Features of CD44+/CD24-low phenotypic cell distribution in relation to predictive markers and molecular subtypes of invasive ductal carcinoma of the breast.
    Gudadze M; Kankava Q; Mariamidze A; Burkadze G
    Georgian Med News; 2014 Mar; (228):81-7. PubMed ID: 24743129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD24 expression in ductal carcinoma in situ and invasive ductal carcinoma of breast: an immunohistochemistry-based pilot study.
    Bircan S; Kapucuoglu N; Baspinar S; Inan G; Candir O
    Pathol Res Pract; 2006; 202(8):569-76. PubMed ID: 16828238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MicroRNA-9 is associated with epithelial-mesenchymal transition, breast cancer stem cell phenotype, and tumor progression in breast cancer.
    Gwak JM; Kim HJ; Kim EJ; Chung YR; Yun S; Seo AN; Lee HJ; Park SY
    Breast Cancer Res Treat; 2014 Aug; 147(1):39-49. PubMed ID: 25086633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinicopathologic correlation of cancer stem cell markers CD44, CD24, VEGF and HIF-1α in ductal carcinoma in situ and invasive ductal carcinoma of breast: an immunohistochemistry-based pilot study.
    Wang Z; Shi Q; Wang Z; Gu Y; Shen Y; Sun M; Deng M; Zhang H; Fang J; Zhang S; Xie F
    Pathol Res Pract; 2011 Aug; 207(8):505-13. PubMed ID: 21802218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clinicopathological significance of CD44+/CD24-/low and CD24+ tumor cells in invasive micropapillary carcinoma of the breast.
    Li W; Liu F; Lei T; Xu X; Liu B; Cui L; Wei J; Guo X; Lang R; Fan Y; Gu F; Tang P; Zhang X; Fu L
    Pathol Res Pract; 2010 Dec; 206(12):828-34. PubMed ID: 20977976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer stem cells markers CD44, CD24 and ALDH1 in breast cancer special histological types.
    de Beça FF; Caetano P; Gerhard R; Alvarenga CA; Gomes M; Paredes J; Schmitt F
    J Clin Pathol; 2013 Mar; 66(3):187-91. PubMed ID: 23112116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transcription factors associated with epithelial-mesenchymal transition and cancer stem cells in the tumor centre and margin of invasive breast cancer.
    Alkatout I; Wiedermann M; Bauer M; Wenners A; Jonat W; Klapper W
    Exp Mol Pathol; 2013 Feb; 94(1):168-73. PubMed ID: 22985790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemical analysis of cancer stem cell markers in invasive breast carcinoma and associated ductal carcinoma in situ: relationships with markers of tumor hypoxia and microvascularity.
    Currie MJ; Beardsley BE; Harris GC; Gunningham SP; Dachs GU; Dijkstra B; Morrin HR; Wells JE; Robinson BA
    Hum Pathol; 2013 Mar; 44(3):402-11. PubMed ID: 23036368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Breast density, scintimammographic (99m)Tc(V)DMSA uptake, and calcitonin gene related peptide (CGRP) expression in mixed invasive ductal associated with extensive in situ ductal carcinoma (IDC + DCIS) and pure invasive ductal carcinoma (IDC): correlation with estrogen receptor (ER) status, proliferation index Ki-67, and histological grade.
    Papantoniou V; Sotiropoulou E; Valsamaki P; Tsaroucha A; Sotiropoulou M; Ptohis N; Stipsanelli A; Dimitrakakis K; Marinopoulos S; Tsiouris S; Antsaklis A
    Breast Cancer; 2011 Oct; 18(4):286-91. PubMed ID: 20143189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunohistological localisation of human FAT1 (hFAT) protein in 326 breast cancers. Does this adhesion molecule have a role in pathogenesis?
    Kwaepila N; Burns G; Leong AS
    Pathology; 2006 Apr; 38(2):125-31. PubMed ID: 16581652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progression of ductal carcinoma in situ to invasive breast cancer is associated with gene expression programs of EMT and myoepithelia.
    Knudsen ES; Ertel A; Davicioni E; Kline J; Schwartz GF; Witkiewicz AK
    Breast Cancer Res Treat; 2012 Jun; 133(3):1009-24. PubMed ID: 22134623
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression profiling of in vivo ductal carcinoma in situ progression models identified B cell lymphoma-9 as a molecular driver of breast cancer invasion.
    Elsarraj HS; Hong Y; Valdez KE; Michaels W; Hook M; Smith WP; Chien J; Herschkowitz JI; Troester MA; Beck M; Inciardi M; Gatewood J; May L; Cusick T; McGinness M; Ricci L; Fan F; Tawfik O; Marks JR; Knapp JR; Yeh HW; Thomas P; Carrasco DR; Fields TA; Godwin AK; Behbod F
    Breast Cancer Res; 2015 Sep; 17():128. PubMed ID: 26384318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lack of expression of androgen receptor may play a critical role in transformation from in situ to invasive basal subtype of high-grade ductal carcinoma of the breast.
    Hanley K; Wang J; Bourne P; Yang Q; Gao AC; Lyman G; Tang P
    Hum Pathol; 2008 Mar; 39(3):386-92. PubMed ID: 18187183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metastasis tumor antigen family proteins during breast cancer progression and metastasis in a reliable mouse model for human breast cancer.
    Zhang H; Stephens LC; Kumar R
    Clin Cancer Res; 2006 Mar; 12(5):1479-86. PubMed ID: 16533771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simultaneous loss of E-cadherin and catenins in invasive lobular breast cancer and lobular carcinoma in situ.
    De Leeuw WJ; Berx G; Vos CB; Peterse JL; Van de Vijver MJ; Litvinov S; Van Roy F; Cornelisse CJ; Cleton-Jansen AM
    J Pathol; 1997 Dec; 183(4):404-11. PubMed ID: 9496256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.